Skip to main content

Table 2 Crude and world- and Europe standardized incidence rates (per 105 person-years) for the overall population and for each molecular subtype, by year, from 2007 to 2012

From: Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries

Year of diagnosis

2007

2008

2009

2010

2011

2012

Crude incidence rate (IR)

      

 Overall

170.99

166.88

159.45

177.99

170.83

171.37

 TN

15.88

16.80

14.23

13.70

16.28

16.48

 HR+/HER2+

9.59

11.10

10.36

11.41

9.38

13.00

 HR+/HER2-

110.23

106.95

107.13

121.43

118.90

114.76

 HR-/HER2+

5.65

5.28

5.65

6.75

6.59

6.45

World Standardized IR

      

 Overall

116.84

113.77

109.67

119.35

114.59

113.89

 TN

11.96

13.00

10.43

9.85

11.22

12.00

 HR+/HER2+

6.70

8.26

8.37

8.74

7.26

10.03

 HR+/HER2-

75.78

73.03

72.73

82.07

79.68

75.21

 HR-/HER2+

4.10

4.08

4.53

5.00

4.94

4.48

Europe Standardized IR

      

 Overall

154.27

149.78

142.02

157.86

150.87

149.10

 TN

15.35

15.95

13.11

12.52

13.85

14.85

 HR+/HER2+

8.37

10.65

10.20

11.18

9.32

11.88

 HR+/HER2-

100.97

96.98

95.48

108.85

106.15

100.69

 HR-/HER2+

4.90

4.99

5.35

6.33

6.09

5.61

  1. TN: Triple Negative; HR: Hormone Receptors; HER: Human epidermal growth factor